Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2010 May 18;17(5):415-6.
doi: 10.1016/j.ccr.2010.04.022.

Coordinate transcriptional regulation by ERG and androgen receptor in fusion-positive prostate cancers

Yu Chen  1 , Charles L Sawyers
Affiliations
Comment

Coordinate transcriptional regulation by ERG and androgen receptor in fusion-positive prostate cancers

Yu Chen et al. Cancer Cell. .

Abstract

In this issue of Cancer Cell, Yu and colleagues mapped the genomic binding sites of ERG and androgen receptor, two crucial transcription factors in prostate cancer. There is an extraordinary degree of overlap between binding sites, with the suggestion that ERG inhibits androgen receptor-mediated differentiation and promotes EZH2-mediated dedifferentiation.

PubMed Disclaimer

Figures

Figure 1
Figure 1. Coordinate regulation of target genes by androgen receptor and ERG
AR binding at enhancers of AR target gene causes looping and gene activation. The “GGAA” ETS motif is highly enriched at AR binding sites raising the possibility that an unidentified ETS protein (not ERG) may coordinately regulate transcription in normal prostate cells (top). In ERG+ prostate cancer, ERG now localizes at these sites, perhaps displacing an “endogenous” ETS factor, as well as gene promoters and inhibits AR mediates transcriptional activation.
See this image and copyright information in PMC

Comment on

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Chen CD, Welsbie DS, Tran C, Baek SH, Chen R, Vessella R, Rosenfeld MG, Sawyers CL. Molecular determinants of resistance to antiandrogen therapy. Nat Med. 2004;10:33–39. - PubMed
    1. Hollenhorst PC, Chandler KJ, Poulsen RL, Johnson WE, Speck NA, Graves BJ. DNA specificity determinants associate with distinct transcription factor functions. PLoS Genet. 2009;5:e1000778. - PMC - PubMed
    1. Holzbeierlein J, Lal P, LaTulippe E, Smith A, Satagopan J, Zhang L, Ryan C, Smith S, Scher H, Scardino P, et al. Gene expression analysis of human prostate carcinoma during hormonal therapy identifies androgen-responsive genes and mechanisms of therapy resistance. Am J Pathol. 2004;164:217–227. - PMC - PubMed
    1. King JC, Xu J, Wongvipat J, Hieronymus H, Carver BS, Leung DH, Taylor BS, Sander C, Cardiff RD, Couto SS, et al. Cooperativity of TMPRSS2-ERG with PI3-kinase pathway activation in prostate oncogenesis. Nat Genet. 2009;41:524–526. - PMC - PubMed
    1. Lupien M, Eeckhoute J, Meyer CA, Wang Q, Zhang Y, Li W, Carroll JS, Liu XS, Brown M. FoxA1 translates epigenetic signatures into enhancer-driven lineage-specific transcription. Cell. 2008;132:958–970. - PMC - PubMed

LinkOut - more resources